regulatory approval_eu
saveMinoryx Therapeutics sl — leriglitazone hydrochloride (Regulatory Approval (EU))
community read0 votes
Therapy area: Metabolic Disorders. Indication: Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD))
Therapy area: Metabolic Disorders. Indication: Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD))